Effects of Six-Week Resistance Training with or without Vibration on Metabolic Markers of Bone Metabolism

Acute and protracted effects of resistive exercise (RE) and resistive exercise with whole-body vibration (RVE) on metabolic markers of bone metabolism were investigated. Twenty-six men participated in a randomized training program including RE (n = 13; age = 23.4 ± 1.4 years) or RVE (n = 13; age = 24.3 ± 3.3 years). During the first session, acute C-terminal telopeptide of type I collagen (CTX) responses decreased by 12.9% (standard deviation, SD 13.7%) after 2 min, followed by a 15.5% (SD 36.0%) increase at 75 min after exercise (both p < 0.001). Procollagen type I amino terminal propeptide (P1NP) increased by 12.9% (SD 9.1%) at 2 min (p < 0.001) but no change occurred at 75 min. Sclerostin showed prolonged responses from 2 to 75 min post-exercise in the first session (p < 0.001). Acute responses at the first session were comparable between groups for CTX and P1NP, acute sclerostin responses were substantially greater in RE than in RVE (p = 0.003). No significant differences were noted in the resting baseline levels of CTX, P1NP, or sclerostin from the beginning to the end of the six-week progressive training. The present study therefore did not demonstrate any sizeable enhancement of bone turnover that could match the effects that have been repeatably made in response to countermeasure exercise during bed rest.

Download Full-text

Reduced Bone Mineral Density and Increased Bone Metabolism Rate in Young Adult Patients with 21-Hydroxylase Deficiency

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2005-2823 ◽

2006 ◽

Vol 91 (11) ◽

pp. 4453-4458 ◽

Cited By ~ 47

Author(s):

Mariateresa Sciannamblo ◽

Gianni Russo ◽

Debora Cuccato ◽

Giuseppe Chiumello ◽

Stefano Mora

Keyword(s):

Bone Mineral Density ◽

Alkaline Phosphatase ◽

Bone Metabolism ◽

Type I Collagen ◽

Whole Body ◽

Type I ◽

Healthy Controls ◽

Mineral Density ◽

Specific Alkaline Phosphatase ◽

Bone Specific Alkaline Phosphatase

Abstract Context: Patients with congenital adrenal hyperplasia (CAH) receive glucocorticoids as replacement therapy. Glucocorticoid therapy is the most frequent cause of drug-induced osteoporosis. Objective: The objective of the study was to evaluate bone mineral density (BMD) and bone metabolism in CAH patients. Design: This was a cross-sectional observational study. Setting: The study was conducted at a referral center for pediatric endocrinology. Patients and Other Participants: Thirty young patients with the classical form of CAH (aged 16.4–29.7 yr) treated with glucocorticoid from diagnosis (duration of treatment 16.4–29.5 yr) and 138 healthy controls (aged 16.0–30.0 yr) were enrolled. Main Outcome Measures: BMD was measured in the lumbar spine and whole body by dual-energy x-ray absorptiometry. Bone formation and resorption rates were estimated by serum measurements of bone-specific alkaline phosphatase and C-terminal telopeptide of type I collagen, respectively. Results: CAH patients were shorter than controls (women −6.8 and men −13.3 cm). Therefore, several methods were used to account for the effect of this difference on bone measurements. Whole-body BMD measurements were significantly lower, compared with controls (P < 0.03), after controlling for height (on average −2.5% in females and −9.3% in male patients). No differences were found in lumbar spine measurements. Bone-specific alkaline phosphatase and C-terminal telopeptide of type I collagen serum concentrations were higher in CAH patients than control subjects (P < 0.04). BMD measurements and bone metabolism markers did not correlate with the actual glucocorticoid dose or mean dose over the previous 7 yr. Conclusions: Young adult patients with the classical form of CAH have decreased bone density values, compared with healthy controls. This may put them at risk of developing osteoporosis early in life.

Download Full-text

Severely restricting energy intake for 24 h does not affect markers of bone metabolism at rest or in response to re-feeding

European Journal of Nutrition ◽

10.1007/s00394-020-02186-4 ◽

2020 ◽

Vol 59 (8) ◽

pp. 3527-3535

Author(s):

David J. Clayton ◽

Lewis J. James ◽

Craig Sale ◽

Iain Templeman ◽

James A. Betts ◽

...

Keyword(s):

Bone Metabolism ◽

Energy Intake ◽

Type I Collagen ◽

Plasma Concentrations ◽

Energy Restriction ◽

Type I ◽

Procollagen Type ◽

Markers Of Bone Turnover ◽

Ad Libitum

Abstract Purpose Intermittent energy restriction commonly refers to ad libitum energy intake punctuated with 24 h periods of severe energy restriction. This can improve markers of metabolic health but the effects on bone metabolism are unknown. This study assessed how 24 h severe energy restriction and subsequent refeeding affected markers of bone turnover. Methods In a randomised order, 16 lean men and women completed 2, 48 h trials over 3 days. On day 1, participants consumed a 24 h diet providing 100% [EB: 9.27 (1.43) MJ] or 25% [ER: 2.33 (0.34) MJ] of estimated energy requirements. On day 2, participants consumed a standardised breakfast (08:00), followed by an ad libitum lunch (12:00) and dinner (19:30). Participants then fasted overnight, returning on day 3. Plasma concentrations of C-terminal telopeptide of type I collagen (CTX), procollagen type 1 N-terminal propeptide (P1NP) and parathyroid hormone (PTH) were assessed as indices of bone metabolism after an overnight fast on days 1–3, and for 4 h after breakfast on day 2. Results There were no differences between trials in fasting concentrations of CTX, P1NP or PTH on days 1–3 (P > 0.512). During both trials, consuming breakfast reduced CTX between 1 and 4 h (P < 0.001) and PTH between 1 and 2 h (P < 0.05), but did not affect P1NP (P = 0.773) Postprandial responses for CTX (P = 0.157), P1NP (P = 0.148) and PTH (P = 0.575) were not different between trials. Ad libitum energy intake on day 2 was greater on ER [12.62 (2.46) MJ] than EB [11.91 (2.49) MJ]. Conclusions Twenty-four hour severe energy restriction does not affect markers of bone metabolism.

Download Full-text

Associations of Circulating Osteoglycin With Bone Parameters and Metabolic Markers in Patients With Diabetes

Frontiers in Endocrinology ◽

10.3389/fendo.2021.649718 ◽

2021 ◽

Vol 12 ◽

Author(s):

Jakob Kau Starup-Linde ◽

Rikke Viggers ◽

Bente Langdahl ◽

Soeren Gregersen ◽

Simon Lykkeboe ◽

...

Keyword(s):

Bone Turnover ◽

Bone Turnover Markers ◽

Type I Collagen ◽

Microvascular Complications ◽

Whole Body ◽

Type I ◽

Amino Terminal ◽

Patients With Diabetes ◽

Turnover Markers

ObjectiveCirculating osteoglycin may facilitate the crosstalk between bone and pancreas to empower adaptation of bone mass to whole body energy balance. We aimed to examine whether osteoglycin is associated with bone and metabolic parameters and if osteoglycin levels differ between patients with type 1 and 2 diabetes (T1D and T2D).Design and methodsA cross-sectional study of 190 patients with diabetes mellitus and stable hemoglobin A1c (HbA1c) (97 T1D and 93 T2D) was conducted. S-osteoglycin was analyzed by ELISA. Unpaired t-tests were performed to test differences between patients with T1D and T2D and linear regression analyses were performed to investigate associations between osteoglycin, glycemic markers, bone turnover markers and characteristics.ResultsS-osteoglycin did not differ between patients with T1D and T2D (p=0.10). No associations were present between osteoglycin and age, gender, microvascular complications, HbA1c, or plasma glucose in T1D or T2D patients (p>0.05 for all). S-osteoglycin was not associated with levels of bone turnover markers (C-terminal cross-linked telopeptide of type-I collagen (CTX), P-procollagen type 1 amino terminal propeptide (P1NP), P-osteocalcin (OC), P-sclerostin, S-osteoprotegerin (OPG) or S-Receptor Activator of Nuclear factor Kappa beta Ligand (RANKL)) in neither T1D or T2D patients (p>0.05 for all).ConclusionOsteoglycin levels were similar in T1D and T2D patients. Osteoglycin did not correlate with glucose, HbA1c or any other biochemical marker of bone turnover. Thus, we did not find evidence supporting the existence of an osteoglycin-bone-pancreas axis.Clinical Trial RegistrationClinicalTrials.gov, identifier NCT01870557.

Download Full-text

Bone Metabolism of the Patient with a Malignant Melanoma during the Entry Examination and the Check-up of Whole-body Bone Scintigraphy

Prague Medical Report ◽

10.14712/23362936.2016.14 ◽

2016 ◽

Vol 117 (2-3) ◽

pp. 129-134

Author(s):

Jaroslav Weissensteiner ◽

Eva Babušíková

Keyword(s):

Malignant Melanoma ◽

Bone Metastases ◽

Bone Metabolism ◽

Bone Scintigraphy ◽

Type I Collagen ◽

Tumour Marker ◽

Whole Body ◽

Type I ◽

Negative Finding ◽

Body Bone

Malignant melanoma is a malignancy located predominantly in the skin and the incidence of melanoma increases. We compared the markers of bone metabolism – osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (β-CrossLaps, β-CTx) and tumour marker – human epididymis protein 4 (HE4) in the serum with finding during the entry examination and the check-up of whole-body bone scintigraphy of the patient with a malignant melanoma. Serum concentrations of OC, β-CTx, HE4 were determined in 1 patient (female, age 64 years) with malignant melanoma and correlated with the presence of equivocal bone metastases detected by whole-body bone scintigraphy (the entry examination and check-up after 6 months). Concentrations of bone metabolism markers decreased during six months and we observed progress in bone metastases. The change of the markers levels during the entry examination and the check-up of the whole-body bone scintigraphy with equivocal finding of bone metastases could be a sign of a possible initiating progression of malignant melanoma despite a clinically negative finding that does not prove the progression of the disease.

Download Full-text

Temporal Change in Biomarkers of Bone Turnover Following Late Evening Ingestion of a Calcium-Fortified, Milk-Based Protein Matrix in Postmenopausal Women with Osteopenia

Nutrients ◽

10.3390/nu11061413 ◽

2019 ◽

Vol 11 (6) ◽

pp. 1413

Author(s):

Manjula Hettiarachchi ◽

Rachel Cooke ◽

Catherine Norton ◽

Phil Jakeman

Keyword(s):

Vitamin D ◽

Postmenopausal Women ◽

Bone Remodeling ◽

Type I Collagen ◽

Dietary Intervention ◽

Type I ◽

Protein Matrix ◽

Procollagen Type ◽

Amino Terminal ◽

Fortified Milk

The diurnal rhythm of bone remodeling suggests nocturnal dietary intervention to be most effective. This study investigated the effect of bedtime ingestion of a calcium-fortified, milk-derived protein matrix (MBPM) or maltodextrin (CON) on acute (0–4 h) blood and 24-h urinary change in biomarkers of bone remodeling in postmenopausal women with osteopenia. In CON, participants received 804 ± 52 mg calcium, 8.2 ± 3.2 µg vitamin D and 1.3 ± 0.2 g/kg BM protein per day. MBPM increased calcium intake to 1679 ± 196 mg, vitamin D to 9.2 ± 3.1 µg and protein to 1.6 ± 0.2 g/kg BM. Serum C-terminal cross-linked telopeptide of type I collagen (CTX) and procollagen type 1 amino-terminal propeptide (P1NP), and urinary N-telopeptide cross-links of type I collagen (NTX), pyridinoline (PYD) and deoxypyridinoline (DPD) was measured. Analyzed by AUC and compared to CON, a −32% lower CTX (p = 0.011, d = 0.83) and 24% (p = 0.52, d = 0.2) increase in P1NP was observed for MBPM. Mean total 24 h NTX excreted in MBPM was −10% (p = 0.035) lower than CON. Urinary PYD and DPD were unaffected by treatment. This study demonstrates the acute effects of bedtime ingestion of a calcium-fortified, milk-based protein matrix on bone remodeling.

Download Full-text

Characterization of Mineral and Bone Metabolism Biomarkers in a Chinese Consanguineous Twin Family with Primary Hypertrophic Osteoarthropathy

International Journal of Endocrinology ◽

10.1155/2020/6698878 ◽

2020 ◽

Vol 2020 ◽

pp. 1-6

Author(s):

Na Li ◽

Yuhang Ma ◽

Yun Jiang ◽

Li You ◽

Yunhong Huang ◽

...

Keyword(s):

Bone Metabolism ◽

Type I Collagen ◽

Urinary Calcium ◽

Hypertrophic Osteoarthropathy ◽

Type I ◽

Primary Hypertrophic Osteoarthropathy ◽

Metabolic Markers ◽

Hydroxyvitamin D ◽

Twin Brother ◽

Heterozygous Carriers

Purpose. Primary hypertrophic osteoarthropathy (PHO) is a rare, autosomal, recessive genetic disease characterized by digital clubbing, periostosis, and pachydermia. The underlying cause for the pathogenesis of this disease is a defect in prostaglandin E2 (PGE2) degradation, caused by mutations in HPGD or SLCO2A1. In this study, we describe the clinical characteristics, SLCO2A1 mutations, and bone metabolic markers of a PHO pedigree from a Chinese consanguineous twin family. Methods. Whole blood and urine samples were collected from all the family members. All the exons and exon-intron boundaries of the HPGD and SLCO2A1 genes were amplified using polymerase chain reaction (PCR) and sequenced. The biomarkers of mineral and bone metabolism, including calcium, phosphorus, parathyroid hormone (PTH), 25-hydroxyvitamin D (25(OH)D), bone Gla-protein (BGP), C-terminal telopeptide of type I collagen (β-CTX), and urinary calcium/creatinine ratio (Uca/Ucr) were detected. Results. A homozygous (nonsense) mutation in the SLCO2A1 gene (c.1807C >T/p.R603 ∗ ) was detected in the proband. Five heterozygous carriers were also identified among his relatives, including his twin brother. The serum BGP (225.5 ng/ml), β-CTX (4112 pg/ml), and Uca/Ucr (0.63) levels were significantly elevated, while the 25(OH)D (37.1 nmol/L) level was reduced in the proband. The proband’s twin brother displayed increased levels of β-CTX (901 pg/ml) and insufficiency of 25(OH)D (67.29 nmol/L), while the other heterozygous carriers only displayed 25(OH)D insufficiency. Conclusion. The patients with PHO displayed an active state of bone reconstruction. There may be a lack of vitamin D, accompanied by an increase in BGP and β-CTX levels. Heterozygous mutations of SLCO2A1 might lead to mild PHO.

Download Full-text

Effects of amlodipine on bone metabolism in male albino Wistar rats

Acta Veterinaria Brno ◽

10.2754/avb201180040391 ◽

2011 ◽

Vol 80 (4) ◽

pp. 391-396 ◽

Cited By ~ 1

Author(s):

Iveta Gradošová ◽

Helena Živná ◽

Klára Švejkovská ◽

Vladimír Palička ◽

Aleš Tichý ◽

...

Keyword(s):

Body Weight ◽

Bone Metabolism ◽

Wistar Rats ◽

Type I Collagen ◽

Bone Alkaline Phosphatase ◽

Bone Morphogenetic Protein 2 ◽

Control Group ◽

Type I ◽

Mineral Density ◽

Procollagen Type

Amlodipine (dihydropyridine-type calcium channel blocker) is a widely used agent for the treatment of hypertension in human and veterinary medicine but detailed information about its effects on bone metabolism are missing. Therefore, the aim of our study was to investigate the effect of amlodipine on bone metabolism in male albino Wistar rats. Amlodipine (0.3 mg/100 g body weight; gavage) was administered to 8 rats for 8 weeks. Control group (n = 8) received aqua pro inj. (0.2 ml/100 g body weight; gavage). Bone marker concentrations of carboxy-terminal cross-linking telopeptide of type I collagen (CTX-I) and aminoterminal propeptide of procollagen type I in serum, and of bone alkaline phosphatase (BALP) in both serum and bone homogenate were measured by enzyme immunoassay. We investigated the expression of bone morphogenetic protein 2 (BMP-2) in proximal tibia using Western blotting, and bone mineral density was measured by Dual-energy X-ray Absorptiometry in lumbar and caudal vertebrae and in femoral areas. Mechanical properties of the femurs were measured by three-point bending of the shaft and compression testing of the femoral neck. After 8 weeks of amlodipine administration there was a significant decrease in serum concentrations of BALP (p = 0.0009) and CTX-I (p = 0.003), and the content of BALP in bone homogenate (p = 0.026) compared to the control. In addition, Western blot analysis indicated increased BMP-2 protein concentration after amlodipine administration. Our findings suggest that amlodipine has a retarding influence on bone metabolism in rats by decreasing bone turnover, which probably in consequence increases expression of BMP-2.

Download Full-text

Comparison of the Whole-Body Bone Scintigraphy with Levels of the Markers of Bone Metabolism in Serum of Patients with Malignant Melanoma

Acta Medica Martiniana ◽

10.1515/acm-2015-0001 ◽

2015 ◽

Vol 5 (1) ◽

pp. 5-11 ◽

Cited By ~ 1

Author(s):

J. Weissensteiner ◽

E. Babusikova

Keyword(s):

Malignant Melanoma ◽

Bone Metastases ◽

Bone Metabolism ◽

Bone Scintigraphy ◽

Type I Collagen ◽

Whole Body ◽

Type I ◽

Control Subjects ◽

Body Bone ◽

Physiological Value

Abstract Objective. The aim of this study was to evaluate serum levels of the biochemical markers of bone metabolism: osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (β-CTx) with the presence of bone metastases detected by whole-body bone scintigraphy in patients with malignant melanoma. Methods. We determined the markers of bone metabolism in the serum by electrochemiluminescent immunoanalysis in 14 patients with melanoma and in 10 persons without malignant disease (control subjects). All participants were examined by whole-body bone scintigraphy using hybrid scanner of type BrightView XCT. Results. The bone metastases by whole-body bone scintigraphy were in 5 cases, probably in 3 cases and 6 patients were without bone metastases from 14 patients (4 men, 10 women). The concentration of OC in patients was lower about 25.4% in comparison with control subjects. The concentration of OC in the serum was below physiological value in 6 patients and in 4 cases with bone metastases. The concentration of β-CTx was below physiological value in 3 patients and in 2 cases with bone metastases. Conclusion. We observed lower concentration of osteocalcin in patients with malignant melanoma compared to control subjects and the lowest ostecalcin concentration was observed in patients with bone metastases. We did not observe changes in the concentration of beta-carboxyterminal cross-linked telopeptide of type I collagen compared neither to control subjects nor between patients with or without bone metastases.

Download Full-text

Effect of miR-34a on Postmenopausal Osteoporosis in Rats Through TGFβ/Smad Signaling Pathway

Journal of Biomaterials and Tissue Engineering ◽

10.1166/jbt.2020.2281 ◽

2020 ◽

Vol 10 (4) ◽

pp. 487-492

Author(s):

Junfeng Chen ◽

Xiaojun Guo ◽

Guangjun Zeng ◽

Jianhua Liu

Keyword(s):

Postmenopausal Osteoporosis ◽

Type I Collagen ◽

Type I ◽

Group Model ◽

Model Group ◽

Mineral Density ◽

Metabolic Markers ◽

Trabecular Thickness ◽

Amino Terminal ◽

Smad Signaling Pathway

30 healthy SD rats of three months were chosen and divided randomly into shamed group, model group, miR-34a mimic transfection group, each of 10 cases. Then to detect serum miR-34a level after three months, TGF-β , Smad4 proteins levels by western blot, serum Ca level, bone mineral density (BMD), bone metabolic markers total type I collagen amino-terminal elongation peptide (TPINP), unique sequence of beta-collagen (beta-CTX), Histopathological Observation and Morphometric Detection of Bone after executed. Results The levels of miR-34a, TGF-β, Smad4 in transfection group were significantly higher than the model group, shamed group the least (P < 0 05), while serum Ca level and BMD value were lowest (P < 0 05). What's more, the TPINP and -CTX levels in transfection group were significantly higher than the model group, shamed group the least (P < 0 05). It proved that fractured trabeculae widened spacing and disordered structure, reduction of trabecular area percentage and mean trabecular thickness in model group and transfection group. It may influence postmenopausal osteoporosis in rats via activation of TGFbeta/Smad signalling pathway by higher expression of miR-34a.

Download Full-text

Association between osteoporosis and hepatitis B cirrhosis: a case-control study

African Health Sciences ◽

10.4314/ahs.v20i4.13 ◽

2020 ◽

Vol 20 (4) ◽

pp. 1610-6

Author(s):

Yijin Zhang ◽

Xuesong Gao ◽

Ting Liu ◽

Ping Gao ◽

Hongjie Li ◽

...

Keyword(s):

Lumbar Spine ◽

Hepatitis B ◽

Type I Collagen ◽

Type I ◽

Mineral Density ◽

Procollagen Type ◽

Amino Terminal ◽

Keywords Liver Cirrhosis ◽

Increased Risk ◽

Severe Cirrhosis

Background and aims: Hepatitis B virus (HBV)-related cirrhosis is associated with decreased bone mineral density (BMD); however, the mechanism is yet unknown. To assess the incidence of osteoporosis in patients with HBV-associated cirrhosis and relevant mechanisms. Methods: A total of 80 hospitalized patients with HBV-associated cirrhosis and 80 healthy controls were enrolled. The levels of serum osteocalcin, total procollagen type 1 amino-terminal propeptide, β-C-terminal telopeptide of type I collagen (β-CTX), and 25-hydroxy vitamin D3 (25(OH)D3) was evaluated in the cirrhosis group. Results: The BMDs of the lumbar spine (P<0.001) and hip joints (P=0.015) in the cirrhosis group were significantly lower than those in the controls. The incidence of osteoporosis in the cirrhosis group was significantly higher than that in the con- trol group (P<0.001). Compared to the patients of the Child-Pugh grade A and B, the BMD of lumbar spine and 25(OH)D3 was significantly decreased in patients of grade C, while β-CTX was elevated. Patients in the cirrhosis group faced a higher risk of osteoporosis as compared to the controls(P<0.001). Conclusion: Enhanced bone resorption accounted for increased risk of osteoporosis in severe cirrhosis. Thus, HBV-asso- ciated cirrhosis was a risk factor for osteoporosis. Keywords: Liver cirrhosis; bone density; osteoporosis; osteopenia; hepatitis B, chronic.

Download Full-text